2025 has been an exciting year for the DECISION project and one full of collaboration and impact.

One of the year’s early highlights was our networking session at EASL2025 in May, where our consortium shared key findings and engaged with the wider liver research community.

This year also saw the publication of a major study: “Maladaptive emergency granulopoiesis predicts poor outcomes in patients hospitalized with decompensated cirrhosis.” Key insights included:

• Patients with poor outcomes exhibit maladaptive EG signatures, including neutrophil activation and immunosuppressive profiles.
• Specific gene markers may identify those at high risk of ACLF and short-term mortality.
• Targeting maladaptive EG offers a potential avenue for future therapies.

On the clinical side, COMBAT reached 50% patient inclusion, marking a significant milestone.

We concluded the year with our final General Assembly in Bologna, celebrating the exceptional collaboration, dedication, and enthusiasm of all DECISION teams.

Additionally, we released three high-level lectures on Inflammation in AD, Clinical Bioinformatics, and the role of LSECtin, extending the project’s scientific impact.

Though DECISION will officially close soon, we look forward to continuing our collaborative efforts into 2026, finishing strong, and maximizing the impact of our work.

We are pleased to announce the release of a keynote lecture by Prof. Rubén Francés (Miguel Hernández University) as part of the DECISION project’s scientific training series.

In this keynote, Prof. Francés presents an in-depth overview of LSECtin, a regulatory molecule expressed by liver sinusoidal endothelial cells (LSECs), and its essential role in maintaining immune tolerance within the hepatic microenvironment. He discusses how LSECtin expression becomes repressed during cirrhosis, and how its modulation affects inflammatory pathways, endothelial–lymphocyte interactions, and Th17 activity.

The lecture integrates findings from patient samples and preclinical models, offering new insights into mechanisms that drive inflammation and immune dysregulation in advanced chronic liver disease (ACLD).

👉 Watch the keynote here.